Advertisement

Drugs

, Volume 32, Supplement 2, pp 6–14 | Cite as

Sorbitol, Myo-Inositol and Sodium-Potassium ATPase in Diabetic Peripheral Nerve

  • Douglas A. Greene
Section 1 The Polyol Pathway and Complications of Diabetes

Summary

Slowing of nerve conduction, a hallmark of both experimental and human diabetic neuropathy, is improved or corrected by aldose reductase inhibitors such as sorbinil Animal experiments suggest that a myo-inositol-related defect in nerve sodium-potassium adenosine triphosphatase (ATPase) is responsible for the acute reversible slowing of nerve conduction in diabetes mellitus. This myo-inositol-related defect is at present viewed as a cyclic metabolic defect. Aldose reductase inhibitors have been shown to restore to normal both the myo-inositol content and the sodium-potassium ATPase activity of nerve. This suggests that the acute effects of aldose-reductase inhibitors on nerve conduction in both diabetic animals and human patients may be modified by the correction of an underlying myo-inositol-related defect of nerve sodium-potassium ATPase. Furthermore, this myoinositol-related defect may contribute to other biochemical, functional and structural abnormalities of diabetic peripheral neuropathy.

Keywords

Nerve Conduction Diabetic Neuropathy Aldose Reductase Diabetic Peripheral Neuropathy Sorbinil 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Behse F, Buchthal F, Carlsen F. Nerve biopsy and conduction studies in diabetic neuropathy. Journal of Neurology and Psychiatry 40: 1072, 1977CrossRefGoogle Scholar
  2. Boulton AJM, Drury J, Clarke B, Ward JD. Continuous subcutaneous insulin infusion in the management of painful diabetic neuropathy. Diabetes Care 5: 386–390, 1982PubMedCrossRefGoogle Scholar
  3. Bradbury MWB, Crowder J. Compartments and barriers in the sciatic nerve of rabbits. Brain Research 103: 515–526, 1976PubMedCrossRefGoogle Scholar
  4. Brismar T, Sima AAF. Changes in nodal function in nerve fibers of the spontaneously diabetic BB-wistar rat. Potential clamp analysis. Acta Physiologica Scandinavica 113: 499–506, 1981PubMedCrossRefGoogle Scholar
  5. Clements RS. Diabetic neuropathy: new concepts of its etiology. Diabetes 28: 604–611, 1979PubMedGoogle Scholar
  6. Das PK, Bray GM, Aguayo AJ, Rasminsky M. Diminished ouabain sensitive sodium potassium ATPase activity in sciatic nerves of rats with streptozotocin induced diabetes. Experimental Neurology 53: 285–288, 1976PubMedCrossRefGoogle Scholar
  7. Day JF, Thorpe SR, Baynes JW. Non-enzymatically glycosylated albumin. In vitro preparation and isolation from normal human serum. Journal of Biological Chemistry 254: 595–597, 1975Google Scholar
  8. Ellenberg M. Diabetic neuropathy: clinical aspects. Metabolism 25: 1627–1655. 1976PubMedCrossRefGoogle Scholar
  9. Fagius J, Jameson S. Effects of aldose reductase inhibitor treatment in diabetic polyneuropathy: a clinical and neurophysiological study. Journal of Neurology, Neurosurgery and Psychiatry 44: 991–1001, 1981CrossRefGoogle Scholar
  10. Fraser DM, Campbell IW, Ewing DJ, Murray A, Neilson JMJ, et al. Peripheral and autonomie nerve function in newly diagnosed diabetes mellitus. Diabetes 26: 546–550, 1977PubMedCrossRefGoogle Scholar
  11. Gillon KRW, Hawthorne JN. Sorbitol, inositol and nerve conduction in diabetes. Life Sciences 32: 1943–1947, 1983aPubMedCrossRefGoogle Scholar
  12. Gillon KRW, Hawthorne JN. Transport of myo-inositol into endoneurial preparations of sciatic nerve from normal and streptozotocin-diabetic rats. Biochemical Journal 210: 775–781, 1983bPubMedGoogle Scholar
  13. Graf RJ, Halter JB, Haler E, Porte Jr D. Nerve conduction abnormalities in untreated maturity-onset diabetes: relation to levels of fasting plasma glucose and glycosylated hemoglobin. Annals of Internal Medicine 90: 298–303, 1979PubMedGoogle Scholar
  14. Graf RJ, Halter JB, Pfeifer MZ, Haler E, Brozovich F, et al. Glycemic control and nerve conduction abnormalities in non-insulin-dependent diabetic subjects. Annals of Internal Medicine 94: 307–311, 1981PubMedGoogle Scholar
  15. Greene DA. Metabolic abnormalities in diabetic peripheral nerve: relation to impaired function. Metabolism 32: 118–123, 1983PubMedCrossRefGoogle Scholar
  16. Greene DA, Lattimer SA. Sodium- and energy-dependent uptake of myo-inositol by rabbit peripheral nerve. Journal of Clinical Investigation 70: 1009–1018, 1982PubMedCrossRefGoogle Scholar
  17. Greene DA, Lattimer SA. Impaired rat sciatic nerve sodium-potassium adenosine triphosphatase in acute streptozotocin diabetes and its correction by dietary myo-inositol supplementation. Journal of Clinical Investigation 72: 1058–1063, 1983PubMedCrossRefGoogle Scholar
  18. Greene DA, Lattimer SA. Impaired energy utilization and Na-K-ATPase in diabetic peripheral nerve. American Journal of Physiology 246: E311–E318, 1984aPubMedGoogle Scholar
  19. Greene DA, Lattimer SA. Action of sorbinil in diabetic peripheral nerve. Relationship of polyol (sorbitol) pathway inhibition to a myo-inositol-mediated defect in sodium-potassium ATPase activity. Diabetes 33: 712–716, 1984bPubMedCrossRefGoogle Scholar
  20. Greene DA, Winegrad AI. In vitro studies of the substrates for energy production and the effects of insulin on glucose utilization in the neural compartments of peripheral nerve. Diabetes 28: 878–887, 1979PubMedCrossRefGoogle Scholar
  21. Greene DA, Winegrad AI. Effects of acute experimental diabetes on composite energy metabolism in peripheral nerve axons and Schwann cells. Diabetes 30: 967–974, 1981PubMedCrossRefGoogle Scholar
  22. Greene DA, DeJesus PV, Winegrad AI. Effects of insulin and dietary myo-inositol on impaired peripheral motor nerve conduction velocity in acute streptozotocin diabetes. Journal of Clinical Investigation 55: 1326–1336, 1975PubMedCrossRefGoogle Scholar
  23. Greene DA, Brown MJ, Braunstein SN, Schwartz SS, Asbury AK, et al. Comparison of clinical course and sequential electro-physiological tests in diabetics with symptomatic polyneuropathy and its implications for clinical trials. Diabetes 30: 139–147, 1981PubMedCrossRefGoogle Scholar
  24. Greene DA, Yagihashi S, Lattimer SA, Sima AAF. Nerve Na+-K+-ATPase, conduction and myoinositol in the insulin deficient BB rat. American Journal of Physiology 247: E534–E539, 1984PubMedGoogle Scholar
  25. Greene DA, Lattimer SA, Finefold DN, Tamres LK. Impaired Na-dependent amino acid uptake in diabetic peripheral nerve: correction by aldose reductase inhibition or myo-inositol supplementation. Clinical Research 33: 431A, 1985aGoogle Scholar
  26. Greene DA, Lattimer SA, Ulbrecht J, Carroll P. Glucose-induced alterations in nerve metabolism: current perspective on the pathogenesis of diabetic neuropathy, and future directions for research and therapy. Diabetes Care 8: 290–299, 1985bPubMedCrossRefGoogle Scholar
  27. Gregersen G. Variations in motor nerve conduction velocity produced by acute changes in the metabolic state in diabetic patients. Diabetologia 4: 273–277, 1968PubMedCrossRefGoogle Scholar
  28. Gregersen G, Borstin H, Theil P, Servo C. Myoinositol and function of peripheral nerves in human diabetics. Acta Neurologica Scandinavica 58: 241–248, 1978PubMedCrossRefGoogle Scholar
  29. Gregersen G, Bertelsen B, Harbo H, Larsen E, Andersen JR, et al. Oral supplementation of myo-inositol: effects on peripheral nerve function in human diabetics and on the concentration in plasma, erythrocytes, urine and muscle tissue in human diabetics and normals. Acta Neurologica Scandinavica 67: 164–172, 1983PubMedCrossRefGoogle Scholar
  30. Jacobsen J. Peripheral nerves in early experimental diabetes, expansion of the exoneurial space as a cause of increased water content. Diabetologia 14: 113–119, 1978CrossRefGoogle Scholar
  31. Judzewitsch RG, Jaspan JB, Polonsky KS, et al. Aldose reductase inhibition improves nerve conduction velocity in diabetic patients. New England Journal of Medicine 308: 119–125, 1983PubMedCrossRefGoogle Scholar
  32. Kuwabara T, Kinoshita JH, Cogan DG. Electron microscopic study of galactose-induced cataracts. Investigative Ophthalmology and Visual Science 8: 133–149, 1969Google Scholar
  33. Mandersloot JB, Roelofsen B, DeGier J. Phosphatidylinositol as the endogenous activator of the (Na+ + K+)ATPase in microsomes of rabbit kidney. Biochimica et Biophysica Acta 508: 478–485, 1972CrossRefGoogle Scholar
  34. Mayer JH, Tomlinson DR. The influence of aldose reductase inhibition and nerve myo-inositol on axonal transport and nerve conduction velocity in rats with experimental diabetes. Diabetologia 25: 433–438, 1983PubMedCrossRefGoogle Scholar
  35. Mayhew JA, Gillon KRW, Hawthorne JN. Free and lipid inositol, sorbitol and sugars obtained post mortem from diabetic and control subjects. Diabetologia 24: 13–15, 1983PubMedCrossRefGoogle Scholar
  36. McCulloch DK, Campbell IW, Prescott R, Clarke B. Effect of alcohol intake on symptomatic peripheral neuropathy in diabetic men. Diabetes Care 3: 245–247, 1980PubMedCrossRefGoogle Scholar
  37. Nishizuka Y. Protein kinases in signal transduction. TIBS 9: 163–166, 1984Google Scholar
  38. Pietri A, Ehle AL, Raskin P. Changes in nerve conduction velocity after six weeks of glucose regulation with portable insulin infusion pumps. Diabetes 29: 668–671, 1980PubMedCrossRefGoogle Scholar
  39. Pirart J. Diabetes mellitus and its degenerative complications. A prospective study of 4400 patients observed between 1947 and 1973. Diabetes Care 1: 168–188, 252–263, 1978Google Scholar
  40. Ritchie JM. The oxygen consumption of mammalian non-myelinated nerve fibres at rest and during activity. Journal of Physiology (London) 188: 309–329, 1967Google Scholar
  41. Roelofsen B. The (non) specificity in the lipid requirement of the calcium and (sodium plus potassium) transporting adenosine triphosphatases. Life Sciences 29: 2235–2247, 1981PubMedCrossRefGoogle Scholar
  42. Salway JG, Finnegan JA, Barnett D, Whitehead L, Karunanayaka A, et al. Effect of myoinositol on peripheral nerve function in diabetes. Lancet 2: 1282–1284, 1978PubMedCrossRefGoogle Scholar
  43. Service FJ, Rizza RA, Daube JR, Obrien PC, Dyck PJ. Near normoglycemia improved nerve conduction and vibration sensation in diabetic neuropathy. Diabetologia 28: 722–727, 1985PubMedGoogle Scholar
  44. Sima AA, Lattimer SA, Yagihashi S, Greene DA. Axo-glial dysjunction: a novel structural lesion that accounts for poorly reversible slowing of nerve conduction in the spontaneously diabetic bio-breeding rat. Journal of Clinical Investigation 77: 474–484, 1986PubMedCrossRefGoogle Scholar
  45. Streb H, Irvine RF, Berridge MJ, Schulz I. Release of Ca++ from a non-mitochondrial intracellular store in pancreatic acinar cells by inositol 1,4,5 triphosphate. Nature 306: 67–69, 1983PubMedCrossRefGoogle Scholar
  46. Thomas PK, Eliasson SG. Diabetic neuropathy. In Dyck PJ, et al. (Eds) Peripheral neuropathy, pp. 956–981, Saunders, Philadelphia, 1975Google Scholar
  47. Thomas PK, Ward JD, Watkins PJ. Diabetic neuropathy. In Keen et al. (Eds) Complications of diabetes, pp. 109–136, Arnold, London, 1982Google Scholar
  48. Tolaymat A, Roque JL, Russo LS. Improvement of diabetic peripheral neuropathy with the portable insulin infusion pump. Southern Medical Journal 75: 185–189, 1982PubMedCrossRefGoogle Scholar
  49. Trachtenberg MC, Packey DJ, Sweeney T. In vivo functioning of the Na++K+- activated ATPase. Current Topics in Cellular Regulation 19: 159–217, 1981PubMedGoogle Scholar
  50. Troni W, Carta Q, Cantello R, Caselle MT, Rainero I. Peripheral nerve function and metabolic control in diabetes mellitus. Annals of Neurology 16: 178–183, 1984PubMedCrossRefGoogle Scholar
  51. Unakar NJ, Tsui JY, Harding CV. Scanning electron microscopy. Development and reversal of galactose-induced cataracts. Ophthalmology Research 13: 20–35, 1981CrossRefGoogle Scholar
  52. Vlassara H, Brownlee M, Cerami A. Non-enzymatic glycosylation of peripheral nerve protein in diabetes mellitus. Proceedings of the National Academy of Sciences of the United States of America 78: 5190–5192, 1981PubMedCrossRefGoogle Scholar
  53. Ward JD, Fisher DJ, Barnes CG, Jessop JD. Improvement in nerve conduction following treatment in newly diagnosed diabetics. Lancet 1: 428–437, 1971PubMedCrossRefGoogle Scholar
  54. Williams SK, Howarth NL, Devenny JJ, Bitensky MW. Structural and functional consequences of increased tubulin glycosylation in diabetes mellitus. Proceedings of the National Academy of Sciences of the United States of America 79: 6546–6550, 1982PubMedCrossRefGoogle Scholar
  55. Winegrad AI, Greene DA. Diabetic polyneuropathy: the importance of insulin deficiency, hyperglycemia and alterations in myoinositol metabolism in its pathogenesis. New England Journal of Medicine 295: 1416–1420, 1976PubMedCrossRefGoogle Scholar
  56. Yue DK, Hanwell MA, Satchell FM, Turtle JR. The effect of aldose reductase inhibition on motor nerve conduction velocity in diabetic rat. Diabetes 31: 789–794, 1982PubMedCrossRefGoogle Scholar

Copyright information

© ADIS Press Limited 1986

Authors and Affiliations

  • Douglas A. Greene
    • 1
  1. 1.Michigan Diabetes Research and Training CenterUniversity of MichiganAnn ArborUSA

Personalised recommendations